In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk

John R Absher

doi:10.7326/J22-0077

In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk

Ann Intern Med. 2022 Oct;175(10):JC117. doi: 10.7326/J22-0077. Epub 2022 Oct 4.

Author

John R Absher¹

Affiliation

¹ University of South Carolina School of Medicine, Greenville, South Carolina, USA (J.R.A.).

PMID: 36191321
DOI: 10.7326/J22-0077

Abstract

Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607. 35716692.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Double-Blind Method
Humans
Migraine Disorders* / drug therapy
Migraine Disorders* / prevention & control
Treatment Failure
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
eptinezumab